{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:19:50Z","timestamp":1789755590590,"version":"4.0.1"},"reference-count":101,"publisher":"Bentham Science Publishers Ltd.","issue":"5","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The disability and mortality related to Parkinson's disease (PD), a\nneurodegenerative disease, are increasing globally at a faster rate than other neurological disorders.\nWith no permanent cure for PD, there is an urgent need to develop novel and effective\nanti-PD drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Targeting monoamine oxidases (MAO), which catalyze the breakdown of\nneurotransmitters, is one way to treat neurodegenerative diseases. In this context, an initial molecular\ndocking of twenty designed sulfonyl derivatives of benzimidazole against monoamine\noxidase B (MAO-B) associated with PD was conducted using AutoDock Vina.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The results were compared with those of the conventional inhibitors, selegiline and\nrasagiline. Based on the docking score, the in-silico pharmacokinetic properties (ADME),\ndrug-likeness, and toxicity profiles of the newly synthesized molecules were examined using\nSwissADME, PreADMET, ProTox-3.0, vNN, and ADMETlab web tools. Then, twelve potential\nderivatives were synthesized and characterized by IR, 1H-NMR, 13C-NMR, 19F-NMR\n(for some compounds), and mass spectrometry. Derivatives 2cj and 1bj were the two molecules\nhaving the best binding affinity of -11.9 and -11.8 kcal\/mol, respectively, against MAOB,\nexhibiting a higher binding affinity compared to that of some commercially available drugs.\nA 50 ns MD simulation run was performed to observe the stability of the top two docked\ncomplexes, MAO-B-2cj and MAO-B-1bj, in order to further validate the efficacy of those two\nsubstances. Moreover, the MM-PBSA method was used to calculate the final, binding free energy\nof the simulated (MAO-B-2cj) complex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study indicates that the binding affinity of most of the hits was superior to\nthat of known MAO inhibitors; therefore, these newly synthesized benzimidazole derivatives\nmay be developed into essential drug candidates for the treatment of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673337912241007120510","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T02:44:01Z","timestamp":1729824241000},"page":"1096-1119","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, Synthesis, Molecular Docking, Pharmacokinetic Properties, and Molecular Dynamics Simulation of Sulfonyl Derivatives of Benzimidazole against Parkinson\u2019s Disease"],"prefix":"10.2174","volume":"33","author":[{"given":"Subarna","family":"Roy","sequence":"first","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"},{"name":"Department of Chemistry, Indian Institute of Technology Indore, Khandwa Road, Simrol, Madhya Pradesh, 453552, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhankar","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paromita","family":"Dey","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Barman","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagat","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of North Bengal, Darjeeling, West Bengal, 734013, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadeep","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of North Bengal, Darjeeling, West Bengal, 734013, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhan","family":"Debnath","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Netaji Subhash Mahavidyalaya, Udaipur, Tripura, 799114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-2003","authenticated-orcid":true,"given":"Goutam","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Hou Y.","year":"2019","unstructured":"Hou Y.; Dan X.; Babbar M.; Wei Y.; Hasselbalch S.G.; Croteau D.L.; Bohr V.A.; Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol  2019,15(10),565-581","journal-title":"Nat Rev Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.fmre.2022.10.009","volume":"3","author":"Zhang S.","year":"2023","unstructured":"Zhang S.; Dong H.; Bian J.; Li D.; Liu C.; Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. Fundam Res  2023,3(4),505-519","journal-title":"Fundam Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","volume":"266","author":"Lim E.W.","year":"2019","unstructured":"Lim E.W.; Aarsland D.; Ffytche D.; Taddei R.N.; van Wamelen D.J.; Wan Y.M.; Tan E.K.; Ray Chaudhuri K.; Amyloid-\u03b2 and Parkinson\u2019s disease. J Neurol  2019,266(11),2605-2619","journal-title":"J Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-017-0015-3","volume":"3","author":"Klemann C.J.H.M.","year":"2017","unstructured":"Klemann C.J.H.M.; Martens G.J.M.; Sharma M.; Martens M.B.; Isacson O.; Gasser T.; Visser J.E.; Poelmans G.; Integrated molecular landscape of Parkinson\u2019s disease. NPJ Parkinsons Dis  2017,3(1),14","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","volume":"72","author":"Driver J.A.","year":"2009","unstructured":"Driver J.A.; Logroscino G.; Gaziano J.M.; Kurth T.; Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology  2009,72(5),432-438","journal-title":"Neurology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40820-022-00847-z","volume":"14","author":"Cheng G.","year":"2022","unstructured":"Cheng G.; Liu Y.; Ma R.; Cheng G.; Guan Y.; Chen X.; Wu Z.; Chen T.; Anti-parkinsonian therapy: Strategies for crossing the blood\u2013brain barrier and nano-biological effects of nanomaterials. Nano-Micro Lett  2022,14(1),105","journal-title":"Nano-Micro Lett"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe W.","year":"2017","unstructured":"Poewe W.; Seppi K.; Tanner C.M.; Halliday G.M.; Brundin P.; Volkmann J.; Schrag A.E.; Lang A.E.; Parkinson disease. Nat Rev Dis Primers  2017,3(1),17013","journal-title":"Nat Rev Dis Primers"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC201809040","volume":"169","author":"Homayoun H.","year":"2018","unstructured":"Homayoun H.; Parkinson disease. Ann Intern Med  2018,169(5),ITC33-ITC48","journal-title":"Ann Intern Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"Pringsheim T.","year":"2021","unstructured":"Pringsheim T.; Day G.S.; Smith D.B.; Rae-Grant A.; Licking N.; Armstrong M.J.; de Bie R.M.A.; Roze E.; Miyasaki J.M.; Hauser R.A.; Espay A.J.; Martello J.P.; Gurwell J.A.; Billinghurst L.; Sullivan K.; Fitts M.S.; Cothros N.; Hall D.A.; Rafferty M.; Hagerbrant L.; Hastings T.; O\u2019Brien M.D.; Silsbee H.; Gronseth G.; Lang A.E.; Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: A report of the AAN guideline subcommittee. Neurology  2021,97(20),942-957","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"Charvin D.","year":"2018","unstructured":"Charvin D.; Medori R.; Hauser R.A.; Rascol O.; Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat Rev Drug Discov  2018,17(11),804-822","journal-title":"Nat Rev Drug Discov"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"Elkouzi A.","year":"2019","unstructured":"Elkouzi A.; Vedam-Mai V.; Eisinger R.S.; Okun M.S.; Emerging therapies in Parkinson disease \u2014 Repurposed drugs and new approaches. Nat Rev Neurol  2019,15(4),204-223","journal-title":"Nat Rev Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1007\/s00415-022-10963-w","volume":"269","author":"Hansen C.A.","year":"2022","unstructured":"Hansen C.A.; Miller D.R.; Annarumma S.; Rusch C.T.; Ramirez-Zamora A.; Khoshbouei H.; Levodopa-induced dyskinesia: A historical review of Parkinson\u2019s disease, dopamine, and modern advancements in research and treatment. J Neurol  2022,269(6),2892-2909","journal-title":"J Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"Hely M.A.","year":"2005","unstructured":"Hely M.A.; Morris J.G.L.; Reid W.G.J.; Trafficante R.; Sydney multicenter study of Parkinson\u2019s disease: Non\u2010L\u2010dopa\u2013responsive problems dominate at 15 years. Mov Disord  2005,20(2),190-199","journal-title":"Mov Disord"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"Wishart D.S.","year":"2018","unstructured":"Wishart D.S.; Feunang Y.D.; Guo A.C.; Lo E.J.; Marcu A.; Grant J.R.; Sajed T.; Johnson D.; Li C.; Sayeeda Z.; Assempour N.; Iynkkaran I.; Liu Y.; Maciejewski A.; Gale N.; Wilson A.; Chin L.; Cummings R.; Le D.; Pon A.; Knox C.; Wilson M.; DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res  2018,46(D1),D1074-D1082","journal-title":"Nucleic Acids Res"},{"key":"ref=15","author":"Jilani T.N.","year":"2023","unstructured":"Jilani T.N.; Sabir S.; Patel P.; Sharma S.;  Trihexyphenidyl  2023","journal-title":"Trihexyphenidyl"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-008055232-3.61299-1","author":"Corea N.","year":"2007","unstructured":"Corea N.; Benztropine. xPharm: The Comprehensive Pharmacology Reference  2007,1-4","journal-title":"xPharm: The Comprehensive Pharmacology Reference"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ajp.2021.102691","volume":"61","author":"Jiang D.Q.","year":"2021","unstructured":"Jiang D.Q.; Jiang L.L.; Wang Y.; Li M.X.; The role of pramipexole in the treatment of patients with depression and Parkinson\u2019s disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr  2021,61,102691","journal-title":"Asian J Psychiatr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.17925\/ENR.2009.04.02.24","volume":"4","author":"Lloret S.P.","year":"2009","unstructured":"Lloret S.P.; Rascol O.; Rotigotine for the treatment of advanced Parkinson\u2019s disease. Eur Neurol Rev  2009,4(2),24","journal-title":"Eur Neurol Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD-130186","volume":"3","author":"Salat D.","year":"2013","unstructured":"Salat D.; Tolosa E.; Levodopa in the treatment of Parkinson\u2019s disease: Current status and new developments. J Parkinsons Dis  2013,3(3),255-269","journal-title":"J Parkinsons Dis"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1017\/S174823210700002X","volume":"3","author":"P\u00e5lhagen S.E.","year":"2008","unstructured":"P\u00e5lhagen S.E.; Heinonen E.; Use of selegiline as monotherapy and in combination with levodopa in the management of Parkinson\u2019s disease: Perspectives from the MONOCOMB study. Prog Neurother Neuropsychopharmacol  2008,3(1)","journal-title":"Prog Neurother Neuropsychopharmacol"},{"key":"ref=21","first-page":"23","volume":"4","author":"Nayak L.","year":"2008","unstructured":"Nayak L.; Henchcliffe C.; Rasagiline in treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat  2008,4(1),23-32","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1586\/14737175.7.12.1649","volume":"7","author":"Leegwater-Kim J.","year":"2007","unstructured":"Leegwater-Kim J.; Waters C.; Role of tolcapone in the treatment of Parkinson\u2019s disease. Expert Rev Neurother  2007,7(12),1649-1657","journal-title":"Expert Rev Neurother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e0183484","DOI":"10.1371\/journal.pone.0183484","volume":"12","author":"Zhu H.","year":"2017","unstructured":"Zhu H.; Lemos H.; Bhatt B.; Islam B.N.; Singh A.; Gurav A.; Huang L.; Browning D.D.; Mellor A.; Fulzele S.; Singh N.; Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS One  2017,12(9),e0183484","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"Rascol O.","year":"2021","unstructured":"Rascol O.; Fabbri M.; Poewe W.; Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol  2021,20(12),1048-1056","journal-title":"Lancet Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/978-3-030-42319-3_21","author":"Walag A.M.P.","year":"2020","unstructured":"Walag A.M.P.; Ahmed O.; Jeevanandam J.; Akram M.; Ephraim-Emmanuel B.C.; Egbuna C.; Semwal P.; Iqbal M.; Hassan S.; Uba J.O.; Health benefits of organosulfur compounds. Functional Foods and Nutraceuticals  2020,445-472","journal-title":"Functional Foods and Nutraceuticals"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"103068","DOI":"10.1016\/j.arabjc.2021.103068","volume":"14","author":"Osipova V.","year":"2021","unstructured":"Osipova V.; Polovinkina M.; Gracheva Y.; Shpakovsky D.; Osipova A.; Berberova N.; Antioxidant activity of some organosulfur compounds in vitro. Arab J Chem  2021,14(4),103068","journal-title":"Arab J Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/A:1024062330700","volume":"58","author":"Osmont K.S.","year":"2003","unstructured":"Osmont K.S.; Arnt C.R.; Goldman I.L.; Temporal aspects of onion-induced antiplatelet activity. Plant Foods Hum Nutr  2003,58(1),27-40","journal-title":"Plant Foods Hum Nutr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/molecules24091809","volume":"24","author":"Schepetkin I.A.","year":"2019","unstructured":"Schepetkin I.A.; Kirpotina L.N.; Khlebnikov A.I.; Balasubramanian N.; Quinn M.T.; Neutrophil immunomodulatory activity of natural organosulfur compounds. Molecules  2019,24(9),1809","journal-title":"Molecules"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1440-1681.1997.tb01813.x","volume":"24","author":"Moriguchi T.","year":"1997","unstructured":"Moriguchi T.; Saito H.; Nishiyama N.; Anti-ageing effect of aged garlic extract in the inbred brain atrophy mouse model. Clin Exp Pharmacol Physiol  1997,24(3-4),235-242","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"613077","DOI":"10.3389\/fmicb.2021.613077","volume":"12","author":"Bhatwalkar S.B.","year":"2021","unstructured":"Bhatwalkar S.B.; Mondal R.; Krishna S.B.N.; Adam J.K.; Govender P.; Anupam R.; Antibacterial properties of organosulfur compounds of garlic (Allium sativum). Front Microbiol  2021,12,613077","journal-title":"Front Microbiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3390\/pr10102054","volume":"10","author":"Nair A.S.","year":"2022","unstructured":"Nair A.S.; Singh A.K.; Kumar A.; Kumar S.; Sukumaran S.; Koyiparambath V.P.; Pappachen L.K.; Rangarajan T.M.; Kim H.; Mathew B.; FDA-approved trifluoromethyl group-containing drugs: A review of 20 years. Processes (Basel)  2022,10(10),2054","journal-title":"Processes (Basel)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ejmech.2015.11.025","volume":"108","author":"Bastos M.M.","year":"2016","unstructured":"Bastos M.M.; Costa C.C.P.; Bezerra T.C.; da Silva F.C.; Boechat N.; Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. Eur J Med Chem  2016,108,455-465","journal-title":"Eur J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrd1821","volume":"4","author":"Wong D.T.","year":"2005","unstructured":"Wong D.T.; Perry K.W.; Bymaster F.P.; Case history: The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov  2005,4(9),764-774","journal-title":"Nat Rev Drug Discov"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1302835","volume":"2018","author":"Walker C.","year":"2018","unstructured":"Walker C.; Are All Oral COX-2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac. Int J Rheumatol  2018,2018,1-12","journal-title":"Int J Rheumatol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","volume":"62","author":"Nepali K.","year":"2019","unstructured":"Nepali K.; Lee H.Y.; Liou J.P.; Nitro-group-containing drugs. J Med Chem  2019,62(6),2851-2893","journal-title":"J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1086\/647939","volume":"50","author":"L\u00f6fmark S.","year":"2010","unstructured":"L\u00f6fmark S.; Edlund C.; Nord C.E.; Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis  2010,50(Suppl. 1),S16-S23","journal-title":"Clin Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"Gler M.T.","year":"2012","unstructured":"Gler M.T.; Skripconoka V.; Sanchez-Garavito E.; Xiao H.; Cabrera-Rivero J.L.; Vargas-Vasquez D.E.; Gao M.; Awad M.; Park S.K.; Shim T.S.; Suh G.Y.; Danilovits M.; Ogata H.; Kurve A.; Chang J.; Suzuki K.; Tupasi T.; Koh W.J.; Seaworth B.; Geiter L.J.; Wells C.D.; Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med  2012,366(23),2151-2160","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/B978-0-7020-6285-8.00157-X","author":"Kuhlmann F.M.","year":"2017","unstructured":"Kuhlmann F.M.; Fleckenstein J.M.;  Infectious Diseases  2017,1345-1372.e2","journal-title":"Infectious Diseases"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/ph15060717","volume":"15","author":"Noriega S.","year":"2022","unstructured":"Noriega S.; Cardoso-Ortiz J.; L\u00f3pez-Luna A.; Cuevas-Flores M.D.R.; Flores De La Torre J.A.; The diverse biological activity of recently synthesized nitro compounds. Pharmaceuticals (Basel)  2022,15(6),717","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"109102","DOI":"10.1016\/j.steroids.2022.109102","volume":"188","author":"Sen S.","year":"2022","unstructured":"Sen S.; Singh B.; Biswas G.; Corticosteroids: A boon or bane for COVID-19 patients? Steroids  2022,188,109102","journal-title":"Steroids"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e0260853","DOI":"10.1371\/journal.pone.0260853","volume":"16","author":"Bitew M.","year":"2021","unstructured":"Bitew M.; Desalegn T.; Demissie T.B.; Belayneh A.; Endale M.; Eswaramoorthy R.; Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study. PLoS One  2021,16(12),e0260853","journal-title":"PLoS One"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.rechem.2021.100200","volume":"3","author":"Pathare B.","year":"2021","unstructured":"Pathare B.; Bansode T.; Review - Biological active benzimidazole derivatives. Results in Chemistry  2021,3,100200","journal-title":"Results in Chemistry"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.2174\/1381612826666200701160904","volume":"26","author":"Albino S.L.","year":"2020","unstructured":"Albino S.L.; da Silva J.M.; de C Nobre, M.S.; de M E Silva, Y.M.S.; Santos, M.B.; de Ara\u00fajo, R.S.A.; do C A de Lima, M.; Schmitt, M.; de Moura, R.O. Bioprospecting of nitrogenous heterocyclic scaffolds with potential action for neglected parasitosis: A review. Curr Pharm Des  2020,26(33),4112-4150","journal-title":"Curr Pharm Des"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1055\/s-0033-1338627","volume":"46","author":"Abdel-Wahab B.","year":"2014","unstructured":"Abdel-Wahab B.; Shaaban S.; Thiazolothiadiazoles and thiazolooxadiazoles: Synthesis and biological applications. Synthesis  2014,46(13),1709-1716","journal-title":"Synthesis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"130369","DOI":"10.1016\/j.molstruc.2021.130369","volume":"1237","author":"Singh K.","year":"2021","unstructured":"Singh K.; Pal R.; Khan S.A.; Kumar B.; Akhtar M.J.; Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. J Mol Struct  2021,1237,130369","journal-title":"J Mol Struct"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.4155\/fmc-2021-0114","volume":"13","author":"El-Senduny F.F.","year":"2021","unstructured":"El-Senduny F.F.; Shabana S.M.; R\u00f6sel D.; Brabek J.; Althagafi I.; Angeloni G.; Manolikakes G.; Shaaban S.; Urea-functionalized organoselenium compounds as promising anti-HepG2 and apoptosis-inducing agents. Future Med Chem  2021,13(19),1655-1677","journal-title":"Future Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2174\/1871520616666151103113412","volume":"16","author":"Yadav S.","year":"2016","unstructured":"Yadav S.; Narasimhan B.; kaur, H. Perspectives of benzimidazole derivatives as anticancer agents in the new era. Anticancer Agents Med Chem  2016,16(11),1403-1425","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11094-019-01976-3","volume":"53","author":"Kanwal A.","year":"2019","unstructured":"Kanwal A.; Ahmad M.; Aslam S.; Naqvi S.A.R.; Saif M.J.; Recent advances in antiviral benzimidazole derivatives: A mini review. Pharm Chem J  2019,53(3),179-187","journal-title":"Pharm Chem J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jhet.5570240107","volume":"24","author":"Iemura R.","year":"1987","unstructured":"Iemura R.; Kawashima T.; Fukuda T.; Ito K.; Tsukamoto G.; Synthesis of benzimidazole derivatives as potential H 1 \u2010antihistaminic agents. J Heterocycl Chem  1987,24(1),31-37","journal-title":"J Heterocycl Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ejmech.2014.01.030","volume":"76","author":"Gaba M.","year":"2014","unstructured":"Gaba M.; Singh S.; Mohan C.; Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents. Eur J Med Chem  2014,76,494-505","journal-title":"Eur J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1016\/j.bmc.2012.09.013","volume":"20","author":"Bansal Y.","year":"2012","unstructured":"Bansal Y.; Silakari O.; The therapeutic journey of benzimidazoles: A review. Bioorg Med Chem  2012,20(21),6208-6236","journal-title":"Bioorg Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1086-5802(16)31036-1","volume":"40","author":"Welage L.S.","year":"2000","unstructured":"Welage L.S.; Berardi R.R.; Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc  2000,40(1),52-62","journal-title":"J Am Pharm Assoc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/antiox11050884","volume":"11","author":"Anastassova N.","year":"2022","unstructured":"Anastassova N.; Aluani D.; Hristova-Avakumova N.; Tzankova V.; Kondeva-Burdina M.; Rangelov M.; Todorova N.; Yancheva D.; Study on the neuroprotective, radical-scavenging and mao-b inhibiting properties of new benzimidazole arylhydrazones as potential multi-target drugs for the treatment of Parkinson\u2019s disease. Antioxidants  2022,11(5),884","journal-title":"Antioxidants"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/10426507.2022.2150852","volume":"198","author":"Roy S.","year":"2023","unstructured":"Roy S.; Sen S.; Saha S.; Deb S.K.; Singh B.; Biswas G.; Design, synthesis and molecular docking studies of 5-fluoro 1-aryl\/alkyl sulfonyl benzimidazole derivatives for treatment of Parkinson\u2019s disease. Phosphorus Sulfur Silicon Relat Elem  2023,198(4),336-344","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.1021\/jm0506266","volume":"48","author":"Binda C.","year":"2005","unstructured":"Binda C.; Hub\u00e1lek F.; Li M.; Herzig Y.; Sterling J.; Edmondson D.E.; Mattevi A.; Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. J Med Chem  2005,48(26),8148-8154","journal-title":"J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; Sanner M.F.; Belew R.K.; Goodsell D.S.; Olson A.J.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem  2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"O\u2019Boyle N.M.","year":"2011","unstructured":"O\u2019Boyle N.M.; Banck M.; James C.A.; Morley C.; Vandermeersch T.; Hutchison G.R.; Open Babel: An open chemical toolbox. J Cheminform  2011,3(1),33","journal-title":"J Cheminform"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"123877","DOI":"10.1016\/j.molliq.2023.123877","author":"Sen S.","year":"2023","unstructured":"Sen S.; Baildya N.; Alphonse-Mendoza M.; Singh B.; Chakraborty S.; Nath Ghosh N.; Biswas G.; Experimental and theoretical study on supramolecular encapsulation of molnupiravir by cucurbit[7]uril: A potential formulating agent for COVID-19. J Mol Liq  2023,123877","journal-title":"J Mol Liq"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2009","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem  2009,31(2),451-461","journal-title":"J Comput Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5958\/0974-4150.2021.00014.6","volume":"14","author":"Pawar S.S.","year":"2021","unstructured":"Pawar S.S.; Rohane S.H.; Review on discovery studio: An important tool for molecular docking. Asian J Res Chem  2021,14(1),1-3","journal-title":"Asian J Res Chem"},{"key":"ref=61","year":"2024","unstructured":"Introducing PyMOL 3.0 Available from:  https:\/\/www.pymol.org\/2024"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep  2017,7(1),42717","journal-title":"Sci Rep"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"103470","DOI":"10.1016\/j.etap.2020.103470","volume":"80","author":"Viana Nunes A.M.","year":"2020","unstructured":"Viana Nunes A.M.; das Chagas Pereira de Andrade, F.; Filgueiras, L.A.; de Carvalho Maia, O.A.; Cunha, R.L.O.R.; Rodezno, S.V.A.; Maia Filho, A.L.M.; de Amorim Carvalho, F.A.; Braz, D.C.; Mendes, A.N. preADMET analysis and clinical aspects of dogs treated with the Organotellurium compound RF07: A possible control for canine visceral leishmaniasis? Environ Toxicol Pharmacol  2020,80,103470","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.theochem.2008.11.021","volume":"897","author":"Remko M.","year":"2009","unstructured":"Remko M.; Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. J Mol Struct Theochem  2009,897(1-3),73-82","journal-title":"J Mol Struct Theochem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13321-018-0283-x","volume":"10","author":"Dong J.","year":"2018","unstructured":"Dong J.; Wang N.N.; Yao Z.J.; Zhang L.; Cheng Y.; Ouyang D.; Lu A.P.; Cao D.S.; ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform  2018,10(1),29","journal-title":"J Cheminform"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fphar.2017.00889","volume":"8","author":"Schyman P.","year":"2017","unstructured":"Schyman P.; Liu R.; Desai V.; Wallqvist A.; vNN web server for ADMET predictions. Front Pharmacol  2017,8,889","journal-title":"Front Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"Banerjee P.","year":"2024","unstructured":"Banerjee P.; Kemmler E.; Dunkel M.; Preissner R.; ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res  2024,52(W1),W513-W520","journal-title":"Nucleic Acids Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejmech.2014.11.020","volume":"90","author":"Cai H.","year":"2015","unstructured":"Cai H.; Liu Q.; Gao D.; Wang T.; Chen T.; Yan G.; Chen K.; Xu Y.; Wang H.; Li Y.; Zhu W.; Novel fatty acid binding protein 4 (FABP4) inhibitors: Virtual screening, synthesis and crystal structure determination. Eur J Med Chem  2015,90,241-250","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"8282","DOI":"10.1039\/C6NJ01721E","volume":"40","author":"Gao X.","year":"2016","unstructured":"Gao X.; Yu B.; Mei Q.; Yang Z.; Zhao Y.; Zhang H.; Hao L.; Liu Z.; Atmospheric CO2 promoted synthesis of N-containing heterocycles over B(C6F5)3 catalyst. New J Chem  2016,40(10),8282-8287","journal-title":"New J Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1021\/jo1021426","volume":"76","author":"Peng J.","year":"2011","unstructured":"Peng J.; Ye M.; Zong C.; Hu F.; Feng L.; Wang X.; Wang Y.; Chen C.; Copper-catalyzed intramolecular C-N bond formation: A straightforward synthesis of benzimidazole derivatives in water. J Org Chem  2011,76(2),716-719","journal-title":"J Org Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jhet.3777","volume":"57","author":"Cheddie A.","year":"2020","unstructured":"Cheddie A.; Shintre S.A.; Bantho A.; Mocktar C.; Koorbanally N.A.; Synthesis and antibacterial activity of a series of 2\u2010trifluoromethylbenzimidazole\u2010thiazolidinone derivatives. J Heterocycl Chem  2020,57(1),299-307","journal-title":"J Heterocycl Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.tet.2014.11.066","volume":"71","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Huang R.; Marrot J.; Coeffard V.; Xiong Y.; Hypervalent iodine-mediated synthesis of benzoxazoles and benzimidazoles via an oxidative rearrangement. Tetrahedron  2015,71(4),700-708","journal-title":"Tetrahedron"},{"key":"ref=73","first-page":"54","volume":"14","author":"Hasan M.","year":"1992","unstructured":"Hasan M.; Rashid N.; Malik F.; Akhtar K.; Osman S.; Duddeck H.; Preparation, separation and NMR spectral peak assignment of regio-isomeric unsymmetrical benzimidazoles. J Chem Soc Pak  1992,14(1),54-59","journal-title":"J Chem Soc Pak"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"14738","DOI":"10.1021\/acs.joc.2c02071","volume":"87","author":"Yu X.","year":"2022","unstructured":"Yu X.; Ma Z.; Zhu W.; Liu H.; Zhang Z.; Liu Y.; Zhang M.; Zhao J.; Zhang P.; Xia C.; Tandem reduction, ammonolysis, condensation, and deamination reaction for synthesis of benzothiadiazines and 1-(phenylsulfonyl)-1 H -benzimidazoles. J Org Chem  2022,87(21),14738-14752","journal-title":"J Org Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"Van Der Spoel D.","year":"2005","unstructured":"Van Der Spoel D.; Lindahl E.; Hess B.; Groenhof G.; Mark A.E.; Berendsen H.J.C.; GROMACS: Fast, flexible, and free. J Comput Chem  2005,26(16),1701-1718","journal-title":"J Comput Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1021\/jp410344g","volume":"118","author":"Lee S.","year":"2014","unstructured":"Lee S.; Tran A.; Allsopp M.; Lim J.B.; H\u00e9nin J.; Klauda J.B.; CHARMM36 united atom chain model for lipids and surfactants. J Phys Chem B  2014,118(2),547-556","journal-title":"J Phys Chem B"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"Vanommeslaeghe K.","year":"2010","unstructured":"Vanommeslaeghe K.; Hatcher E.; Acharya C.; Kundu S.; Zhong S.; Shim J.; Darian E.; Guvench O.; Lopes P.; Vorobyov I.; Mackerell A.D.; CHARMM general force field: A force field for drug\u2010like molecules compatible with the CHARMM all\u2010atom additive biological force fields. J Comput Chem  2010,31(4),671-690","journal-title":"J Comput Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/ci300363c","volume":"52","author":"Vanommeslaeghe K.","year":"2012","unstructured":"Vanommeslaeghe K.; MacKerell A.D.; Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing. J Chem Inf Model  2012,52(12),3144-3154","journal-title":"J Chem Inf Model"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"Kumari R.","year":"2014","unstructured":"Kumari R.; Kumar R.; Lynn A.; g_mmpbsa - A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model  2014,54(7),1951-1962","journal-title":"J Chem Inf Model"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","volume":"15","author":"De Virgilio A.","year":"2016","unstructured":"De Virgilio A.; Greco A.; Fabbrini G.; Inghilleri M.; Rizzo M.I.; Gallo A.; Conte M.; Rosato C.; Ciniglio Appiani M.; de Vincentiis M.; Parkinson\u2019s disease: Autoimmunity and neuroinflammation. Autoimmun Rev  2016,15(10),1005-1011","journal-title":"Autoimmun Rev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","volume":"27","author":"Ellis J.M.","year":"2017","unstructured":"Ellis J.M.; Fell M.J.; Current approaches to the treatment of Parkinson\u2019s Disease. Bioorg Med Chem Lett  2017,27(18),4247-4255","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/13543776.2022.2083501","volume":"32","author":"Guglielmi P.","year":"2022","unstructured":"Guglielmi P.; Carradori S.; D\u2019Agostino I.; Campestre C.; Petzer J.P.; An updated patent review on monoamine oxidase (MAO) inhibitors. Expert Opin Ther Pat  2022,32(8),849-883","journal-title":"Expert Opin Ther Pat"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/molecules21010075","volume":"21","author":"Mao F.","year":"2016","unstructured":"Mao F.; Ni W.; Xu X.; Wang H.; Wang J.; Ji M.; Li J.; Chemical structure-related drug-like criteria of global approved drugs. Molecules  2016,21(1),75","journal-title":"Molecules"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/molecules27051643","volume":"27","author":"Benedetto Tiz D.","year":"2022","unstructured":"Benedetto Tiz D.; Bagnoli L.; Rosati O.; Marini F.; Sancineto L.; Santi C.; New halogen-containing drugs approved by FDA in 2021: An overview on their syntheses and pharmaceutical use. Molecules  2022,27(5),1643","journal-title":"Molecules"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"47606","DOI":"10.1021\/acsomega.3c05719","volume":"8","author":"Jayan J.","year":"2023","unstructured":"Jayan J.; Lee J.; Kumar S.; Manoharan A.; Narayanan A.P.; Jauhari R.; Abdelgawad M.A.; Ghoneim M.M.; Ebrahim H.A.; Mary Zachariah S.; Kim H.; Mathew B.; Development of a new class of monoamine oxidase-B inhibitors by fine-tuning the halogens on the acylhydrazones. ACS Omega  2023,8(50),47606-47615","journal-title":"ACS Omega"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.ijbiomac.2017.05.162","volume":"104","author":"Mathew B.","year":"2017","unstructured":"Mathew B.; Mathew G.E.; Ucar G.; Joy M.; Nafna E.K.; Lohidakshan K.K.; Suresh J.; Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. Int J Biol Macromol  2017,104(Pt A),1321-1329","journal-title":"Int J Biol Macromol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/ph16081157","volume":"16","author":"Pinheiro P.S.M.","year":"2023","unstructured":"Pinheiro P.S.M.; Franco L.S.; Fraga C.A.M.; The magic methyl and its tricks in drug discovery and development. Pharmaceuticals (Basel)  2023,16(8),1157","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"115167","DOI":"10.1016\/j.poly.2021.115167","volume":"201","author":"Adam M.S.S.","year":"2021","unstructured":"Adam M.S.S.; Abu-Dief A.M.; Makhlouf M.M.; Shaaban S.; Alzahrani S.O.; Alkhatib F.; Masaret G.S.; Mohamed M.A.; Alsehli M.; El-Metwaly N.M.; Mohamad A.D.M.; Tailoring, structural inspection of novel oxy and non-oxy metal-imine chelates for DNA interaction, pharmaceutical and molecular docking studies. Polyhedron  2021,201,115167","journal-title":"Polyhedron"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/inorganics11080321","volume":"11","author":"Shaaban S.","year":"2023","unstructured":"Shaaban S.; Al-Faiyz Y.S.; Alsulaim G.M.; Alaasar M.; Amri N.; Ba-Ghazal H.; Al-Karmalawy A.A.; Abdou A.; Synthesis of new organoselenium-based succinanilic and maleanilic derivatives and in silico studies as possible SARS-CoV-2 main protease inhibitors. Inorganics (Basel)  2023,11(8),321","journal-title":"Inorganics (Basel)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev  2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13065-017-0362-5","volume":"11","author":"Pathak M.","year":"2017","unstructured":"Pathak M.; Ojha H.; Tiwari A.K.; Sharma D.; Saini M.; Kakkar R.; Design, synthesis and biological evaluation of antimalarial activity of new derivatives of 2,4,6-s-triazine. Chem Cent J  2017,11(1),132","journal-title":"Chem Cent J"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/js9804011","volume":"88","author":"Clark D.E.","year":"1999","unstructured":"Clark D.E.; Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci  1999,88(8),807-814","journal-title":"J Pharm Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1021\/acsmedchemlett.9b00489","volume":"11","author":"Landry M.L.","year":"2020","unstructured":"Landry M.L.; Crawford J.J.; Log D.; Log D contributions of substituents commonly used in medicinal chemistry. ACS Med Chem Lett  2020,11(1),72-76","journal-title":"ACS Med Chem Lett"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"104713","DOI":"10.1016\/j.bioorg.2021.104713","volume":"109","author":"Shaaban S.","year":"2021","unstructured":"Shaaban S.; Shabana S.M.; Al-Faiyz Y.S.; Manolikakes G.; El-Senduny F.F.; Enhancing the chemosensitivity of HepG2 cells towards cisplatin by organoselenium pseudopeptides. Bioorg Chem  2021,109,104713","journal-title":"Bioorg Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1080\/07391102.2022.2141895","volume":"41","author":"Sharma B.","year":"2022","unstructured":"Sharma B.; Bhattacherjee D.; Zyryanov G.V.; Purohit R.; An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders. J Biomol Struct Dyn  2022,41(19),9424-9436","journal-title":"J Biomol Struct Dyn"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"34984","DOI":"10.1038\/srep34984","volume":"6","author":"Aier I.","year":"2016","unstructured":"Aier I.; Varadwaj P.K.; Raj U.; Structural insights into conformational stability of both wild-type and mutant EZH2 receptor. Sci Rep  2016,6(1),34984","journal-title":"Sci Rep"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3390\/v14112436","volume":"14","author":"Alomair L.","year":"2022","unstructured":"Alomair L.; Mustafa S.; Jafri M.S.; Alharbi W.; Aljouie A.; Almsned F.; Alawad M.; Bokhari Y.A.; Rashid M.; Molecular dynamics simulations to decipher the role of phosphorylation of SARS-CoV-2 Nonstructural Proteins (nsps) in viral replication. Viruses  2022,14(11),2436","journal-title":"Viruses"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/S0026893308040195","volume":"42","author":"Lobanov M.Y.","year":"2008","unstructured":"Lobanov M.Y.; Bogatyreva N.S.; Galzitskaya O.V.; Radius of gyration as an indicator of protein structure compactness. Mol Biol  2008,42(4),623-628","journal-title":"Mol Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"130094","DOI":"10.1016\/j.molstruc.2021.130094","volume":"1233","author":"Bhowmik D.","year":"2021","unstructured":"Bhowmik D.; Sharma R.D.; Prakash A.; Kumar D.; Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CLpro and PLpro. J Mol Struct  2021,1233,130094","journal-title":"J Mol Struct"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1006\/jmbi.1994.1017","volume":"235","author":"Maiorov V.N.","year":"1994","unstructured":"Maiorov V.N.; Crippen G.M.; Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins. J Mol Biol  1994,235(2),625-634","journal-title":"J Mol Biol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1080\/07391102.2023.2206911","volume":"42","author":"Pandey B.","year":"2023","unstructured":"Pandey B.; Grover A.; Mechanistic and structural insight into R2R3-MYB transcription factor in plants: Molecular dynamics based binding free energy analysis. J Biomol Struct Dyn  2023,42(5),2632-2642","journal-title":"J Biomol Struct Dyn"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673337912241007120510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235673\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673337912241007120510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:29:02Z","timestamp":1771216142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235673\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673337912241007120510","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}